Vascular characterisation of triple negative breast carcinomas using dynamic MRI

European Radiology

Volumn 21, Issue 7, 2011, Pages 1364-1373

  Li, Sonia P ^a   Padhani, Anwar R ^b   Taylor, N Jane ^b   Beresford, Mark J ^a   Ah See, Mei Lin W ^a   Stirling, J James ^b   D'Arcy, James A ^c   Collins, David J ^c   Makris, Andreas ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Angiogenesis; Breast neoplasms; Functional; Magnetic resonance imaging; Pathological; Permeability; Triple negative breast cancers

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; FEMALE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIOLOGICAL PARAMETERS; TECHNIQUE; TRIPLE NEGATIVE BREAST CANCER; TUMOR VASCULARIZATION;

ADULT; AGED; AREA UNDER CURVE; BIOPSY, NEEDLE; BLOOD FLOW VELOCITY; BLOOD VOLUME; BREAST NEOPLASMS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; ROC CURVE; STATISTICS, NONPARAMETRIC;

EID: 79959374405     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-011-2061-2     Document Type: Article

References (42)

1. WL Irvin Jr LA Carey 2008 What is triple-negative breast cancer? Eur J Cancer 44 2799 2805 19008097 10.1016/j.ejca.2008.09.034 1:CAS:528: DC%2BD1cXhsVKltr%2FE
2. A Bosch P Erole R Zaragoza JR Vina A Lluch 2010 Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research Cancer Treat Rev 36 206 215 20060649 10.1016/j.ctrv.2009.12.002 1:CAS:528:DC%2BC3cXksFChsbo%3D
3. CM Perou T Sorlie MB Eisen M van de Rijn SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen LA Akslen O Fluge A Pergamenschikov C Williams SX Zhu PE Lonning A-L Borresen-Dale PO Brown D Botstein 2000 Molecular portraits of human breast tumours Nature 406 747 752 10963602 10.1038/35021093 1:CAS:528: DC%2BD3cXmt1CnsLw%3D
4. T Sorlie CM Perou R Tibshirani T Aas S Geisler H Johnsen T Hastie MB Eisen M van de Rijn SS Jeffrey T Thorsen H Quist JC Matese PO Brown D Botstein P Eystein Lønning AL Børresen-Dale 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 10874 11553815 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D (Pubitemid 32878711)
5. EA Rakha IO Ellis 2009 Triple-negative/basal-like breast cancer: a review Pathology 41 1 40 47 19089739 10.1080/00313020802563510
6. B Kreike MJ van de Vijver 2007 Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res 9 405 10.1186/bcr1832
7. DJ Collins AR Padhani 2004 Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges IEEE Eng Med Biol Mag 23 65 83 15565801 10.1109/MEMB.2004.1360410 (Pubitemid 39545969)
8. JH Chen G Agrawal B Feig HM Baek PM Carpenter RS Mehta O Nalcioglu M-Y Su 2007 Triple-negative breast cancer: MRI features in 29 patients Ann Oncol 18 2042 2043 18029970 10.1093/annonc/mdm504 Letters to the editor (Pubitemid 350286248)
9. S Basu W Chen J Tchou A Mavi T Cermik B Czerniecki M Schnall A Alavi 2008 Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters Cancer 112 995 1000 18098228 10.1002/cncr.23226 1:CAS:528:DC%2BD1cXjs1eqsLo%3D (Pubitemid 351304582)
10. MW Ah-See A Makris NJ Taylor M Harrison PI Richman RJ Burcombe JJ Stirling JA d'Arcy DJ Collins MR Pittam D Ravichandran AR Padhani 2008 Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer Clin Cancer Res 14 6580 6589 18927299 10.1158/1078-0432.CCR-07-4310 1:CAS:528:DC%2BD1cXht1KgtbfK
11. Sobin LH, Wittekind C (2002) TNM classification of malignant tumours. Wiley-Liss, UICC, New York
12. HJG Bloom WW Richardson 1957 Histological grading and prognosis in breast cancer Br J Cancer 11 359 377 13499785 10.1038/bjc.1957.43 1:STN:280: DyaG1c%2Fkt1Gmtg%3D%3D
13. JM Harvey GM Clark CK Osborne DC Allred 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 1474 1481 10334533 1:STN:280:DyaK1M3msFOjsA%3D%3D (Pubitemid 29220854)
14. GJM Parker J Suckling SF Tanner AR Padhani PB Revell JE Husband MO Leach 1997 Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics JMRI 7 564 574 9170043 10.1002/jmri.1880070318 1:STN:280:DyaK2szhtlKnsA%3D%3D (Pubitemid 28360876)
15. SM Galbraith MA Lodge NJ Taylor GJS Rustin S Bentzen JJ Stirling AR Padhani 2002 Reproducibility of dynamic contrast-enhanced MRI in human muscles and tumours: comparison of quantitative and semi-quantitative analysis NMR Biomed 15 132 142 11870909 10.1002/nbm.731 (Pubitemid 34213403)
16. JA d'Arcy DJ Collins AR Padhani S Walker-Samuel J Suckling MO Leach 2006 Magnetic resonance imaging workbench (MRIW): dynamic contrast enhanced MRI data analysis and visualisation Radiographics 26 621 632 16549620 10.1148/rg.262045187 (Pubitemid 43515329)
17. PS Tofts B Berkowitz MD Schnall 1995 Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumor using a permeability model Magn Reson Med 33 564 568 7776889 10.1002/mrm.1910330416 1:STN:280:DyaK2M3psFGlsA%3D%3D
18. T Fritz-Hansen E Rostrup HB Larsson L Sondergaard P Ring O Henriksen 1996 Measurement of the arterial concentration of Gd-DTPA using MRI: a step toward quantitative perfusion imaging Magn Reson Med 36 225 231 8843376 10.1002/mrm.1910360209 1:CAS:528:DyaK28Xlt1Cltbw%3D (Pubitemid 26271742)
19. S Walker-Samuel MO Leach DJ Collins 2006 Evaluation of response to treatment using DCE-MRI: the relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis Phys Med Biol 51 3593 3602 16825751 10.1088/0031-9155/51/14/021 1:STN:280: DC%2BD28vgsFGgtw%3D%3D (Pubitemid 44026420)
20. S Walker-Samuel C Parker MO Leach DJ Collins 2007 Reproducibility of reference tissue quantification of dynamic contrast-enhanced data: comparison with a fixed vascular input function Phys Med Biol 52 75 89 17183129 10.1088/0031-9155/52/1/006 1:STN:280:DC%2BD28jksVylsg%3D%3D (Pubitemid 46646267)
21. CA Livasy G Karaca R Nanda MS Tretiakova OI Olopade DT Moore CM Perou 2006 Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma Mod Pathol 19 264 271 16341146 10.1038/modpathol.3800528 1:CAS:528:DC%2BD28Xlt1eqtw%3D%3D (Pubitemid 43117611)
22. LG Fulford DF Easton JS Reis-Filho A Sofronis CE Gillett SR Lakhani A Hanby 2006 Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of the breast Histopathology 49 22 34 16842243 10.1111/j.1365-2559.2006.02453.x 1:STN:280:DC%2BD28vitFOitQ%3D%3D (Pubitemid 43972917)
23. O Gluz C Liedtke N Gottschalk L Pusztai U Nitz N Harbeck 2009 Triple-negative breast cancer-current status and future directions Ann Oncol 20 1913 1927 19901010 10.1093/annonc/mdp492 1:STN:280:DC%2BD1MjnsVGjug%3D%3D
24. ES Ko BH Lee HA Kim WC Noh MS Kim SA Lee 2010 Triple-negative breast cancer: correlation between imaging and pathological findings Eur Radiol 20 1111 1117 19898850 10.1007/s00330-009-1656-3
25. T Uematsu M Kasami S Yuen 2009 Triple-negative breast cancer: correlation between MR imaging and pathologic findings Radiology 250 638 647 19244039 10.1148/radiol.2503081054
26. J Tchou L-P Wang M Sargen S Sonnad J Tomaszewski M Schnall 2006 Do triple-negative breast cancers have a distinct imaging phenotype? [abstract] Breast Cancer Res Treat 100 s128
27. KA Miles RE Williams 2008 Warburg revisited: imaging tumour blood flow and metabolism Cancer Imaging 8 81 86 18390391 10.1102/1470-7330.2008.0011 1:STN:280:DC%2BD1c3jtlKluw%3D%3D (Pubitemid 351517291)
28. A Bergamaschi E Tagliabue T Sorlie B Naume T Triulzi R Orlandi HG Russnes JM Nesland R Tammi P Auvinen VM Kosma S Ménard AL Borresen-Dale 2008 Extracellular matrix signature identified breast cancer subgroups with different clinical outcome J Pathol 214 357 367 18044827 10.1002/path.2278 1:CAS:528:DC%2BD1cXivVSgt7c%3D (Pubitemid 351212391)
29. WD Foulkes JS Brunet IM Stefansson O Straume PO Chappuis LR Begin N Hamel JR Goffin N Wong M Trudel L Kapusta P Porter LA Akslen 2004 The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid- microvasular proliferation+) phenotype of BRCA1-related breast cancer Cancer Res 64 830 835 14871808 10.1158/0008-5472.CAN-03-2970 1:CAS:528: DC%2BD2cXhtFCgtLo%3D (Pubitemid 38176880)
30. BK Linderholm H Hellborg U Johansson G Ellmberger L Skoog J Lehtio R Lewensohn 2009 Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer Ann Oncol 20 1639 1646 19549711 10.1093/annonc/mdp062 1:STN:280:DC%2BD1MnjvFyitQ%3D%3D
31. BK Linderholm T Lindahl L Holmberg S Klaar J Lennerstrand R Henriksson J Bergh 2001 The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer Cancer Res 61 5407 5414
32. A Greenberg HS Rugo 2010 Triple-negative breast cancer: role of antiangiogenic agents Cancer J 16 33 38 20164688 10.1097/PPO.0b013e3181d38514 1:CAS:528:DC%2BC3cXjvVKkt7c%3D
33. YH Shi L Bingle LH Gong YX Wang KP Corke WG Fang 2007 Basic FGF augments hypoxia induced HIF-1 alpha expression and VEGF release in T47D breast cancer cells Pathology 39 396 400 17676480 10.1080/00313020701444549 1:CAS:528:DC%2BD2sXosFarsro%3D (Pubitemid 47221464)
34. N Raghunand RA Gatenby RJ Gillies 2003 Microenvironmental and cellular consequences of altered blood flow in tumours Br J Radiol 76 S11 S22 15456710 10.1259/bjr/12913493 (Pubitemid 39530312)
35. Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, Tomczak P, Juozaityte E, Harbeck N, Steger GG, the BO17708 Study Group (2009) Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC) [abstract]. 32nd San Antonio Breast Cancer Symposium. Available at http://www.sabcs.org/Newsletter/Docs/SABCS-2009- Issue1.pdf. Accessed 23.9.2010
36. J O'Shaughnessy V Dieras J Glaspy A Brufsky K Miller D Miles P Koralewski S Phan S Bhattacharya 2009 Comparison of subgroup analyses of PFS from three phase II studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC) [abstract] Cancer Res 69 s207 10.1158/0008-5472.SABCS-09-207
37. K Miller M Wang J Gralow M Dickler M Cobleigh EA Perez T Shenkier D Cella NE Davidson 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 18160686 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D
38. N Robert V Dieras J Glaspy A Brufsky I Bondarenko O Lipatov E Perez D Yardley S Phan S Bhattacharya J O'Shaughnessy 2009 Clinical benefit rate and time to response in RIBBON-1, a randomized, double-blind, phase III trial of chemotherapy with or without bevacizumab (B) for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) [abstract] Cancer Res 69 s6084 10.1158/0008-5472.SABCS-09-6084
39. PA Baltzer T Vag M Dietzel S Beger C Freiberg M Gajda O Camara WA Kaiser 2010 Computer-aided interpretation of dynamic magnetic resonance imaging reflects histopathology of invasive breast cancer Eur Radiol 20 1 563 571
40. SJ Dawson E Provenzano C Caldas 2009 Triple negative breast cancers: clinical and prognostic implications Eur J Cancer 45 27 40 19775602 10.1016/S0959-8049(09)70013-9
41. AR Padhani G Liu DM Koh TL Chenevert HC Thoeny T Takahara A Dzik-Jurasz BD Ross M Van Cauteren D Collins DA Hammoud GJ Rustin B Taouli PL Choyke 2009 Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations Neoplasia 11 102 125 19186405 1:CAS:528:DC%2BD1MXhvVOls70%3D
42. SP Li NJ Taylor A Makris ML Ah-See MJ Beresford JJ Stirling JA d'Arcy DJ Collins AR Padhani 2010 Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy Radiology 257 643 652 20858850 10.1148/radiol.10100421 Epub 2010 Sep 21